Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director · President | July 15, 2019 | July 17, 2019 |
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | September 18, 2026 | September 22, 2026 |
| Bruker Cellular Analysis, Inc.BLI · Entity 109250 | Director | May 14, 2021 | May 18, 2021 |
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Chief Business Officer | January 15, 2018 | January 18, 2018 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 18, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 15, 2019 · Filed July 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,888 |
Reported balance
After 2019-07-15 transaction · row 1
1 source rowRow 1 · 2019-07-15 · Sale · Disposed 1,819 · Balance 19,888 F1: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on April 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on April 17, 2018.
Atrium Therapeutics, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,668 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Tax withholding · Disposed 126,418 · Balance 138,668 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Bruker Cellular Analysis, Inc.
Report date May 14, 2021 · Filed May 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,400 |
Reported balance
After 2021-05-14 transaction · row 1
1 source rowRow 1 · 2021-05-14 · Grant · Acquired 1,400 · Balance 1,400 F1: Represents an award of restricted stock units ('RSUs'). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on May 14, 2022 and have no expiration date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.13 · Expires 2031-05-13 | Direct | 4,900 |
Reported balance
After 2021-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-14 · Grant · Acquired 4,900 · Balance 4,900 F2: The stock option will fully vest on May 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ('RSUs'). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on May 14, 2022 and have no expiration date.
F2: The stock option will fully vest on May 14, 2022.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
IONIS PHARMACEUTICALS INC
Report date January 15, 2018 · Filed January 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,931 |
Ending reported balance
After 2018-01-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-01-15 · Exercise / conversion · Acquired 5,367 · Balance 11,127 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Row 2 · 2018-01-16 · Sale · Disposed 2,196 · Balance 8,931 F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,916 |
Reported balance
After 2018-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-15 · Grant · Acquired 12,916 · Balance 12,916 F3: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,427 |
Reported balance
After 2018-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-15 · Exercise / conversion · Disposed 5,367 · Balance 10,427 F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.
F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F3: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
F4: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
OmniAb, Inc.
Report date June 18, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,381 |
Reported balance
After 2024-06-18 transaction · row 1
1 source rowRow 1 · 2024-06-18 · Exercise / conversion · Acquired 20,000 · Balance 68,381 F1: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-18 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2024-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-18 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.19 · Expires 2034-06-18 | Direct | 40,000 |
Reported balance
After 2024-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-18 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 474,861 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2029-12-17 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 386,015 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.34 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2032-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 425,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.57 · Expires 2033-09-10 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2034-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2035-01-05 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,892 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 1,004 · Balance 2,892 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-06-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 4,340 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:20 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | Tax withholdingCommon Stock | 126,418 | $8.95 | $1,131,441.10 |
DisclosureSEC source: 0001193125-26-397951 · ownership.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,668 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 21:42 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001628280-26-045833 · wk-form4_1782510140.xml · derivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Common Stock · 19,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 165,000 | Not disclosed Strike: $31.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 8 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2035-01-05 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | Not disclosed Strike: $10.16 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 7 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2034-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $6.57 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 6 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2033-09-10 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 5 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2033-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 425,000 | Not disclosed Strike: $14.22 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 4 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 425,000 shares Expires 2032-01-20 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | Not disclosed Strike: $22.34 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2031-02-01 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 386,015 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · derivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 386,015 shares Expires 2029-12-17 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:19 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 474,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082275 · ownership.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 23:00 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001193125-26-085922 · ownership.xml · derivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:34 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 7,993 | $72.45 | $579,092.85 |
DisclosureSEC source: 0001599901-26-000025 · wk-form4_1769207639.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,007 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:34 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 6,394 | $72.45 | $463,245.30 |
DisclosureSEC source: 0001599901-26-000025 · wk-form4_1769207639.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 277,000 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:13 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 8,576 | $72.23 | $619,444.48 |
DisclosureSEC source: 0001599901-26-000014 · wk-form4_1767996793.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,394 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 13:27 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GiftCommon Stock | 29,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000219 · wk-form4_1766150855.xml · nonDerivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,970 F3 · shares: Represents a gift of shares to a Donor Advised Fund. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:27 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Tax withholdingCommon Stock | 15,742 | $71.87 | $1,131,377.54 |
DisclosureSEC source: 0001599901-25-000219 · wk-form4_1766150855.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,129 F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:27 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000219 · wk-form4_1766150855.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,871 F1 · shares: Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 22:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-25-000175 · wk-form4_1757112957.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,022,015 Underlying: Common Stock · 50,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person. F3 · derivative.exercise_date: This option award is fully vested and exercisable as of the date hereof. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 22:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 50,000 | $49.95 | $2,497,435.00 |
DisclosureSEC source: 0001599901-25-000175 · wk-form4_1757112957.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,871 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.76 to $50.12. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 22:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 50,000 | $1.24 | $62,000.00 |
DisclosureSEC source: 0001599901-25-000175 · wk-form4_1757112957.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person. Read SEC document |
| August 28, 2025 Filed Aug 29, 2025 20:28 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-25-000168 · wk-form4_1756499311.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,015 Underlying: Common Stock · 25,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person. F3 · derivative.exercise_date: This option award is fully vested and exercisable as of the date hereof. Read SEC document |
| August 28, 2025 Filed Aug 29, 2025 20:28 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 25,000 | $49.39 | $1,234,700.00 |
DisclosureSEC source: 0001599901-25-000168 · wk-form4_1756499311.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,871 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.23 to $49.52. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 28, 2025 Filed Aug 29, 2025 20:28 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 25,000 | $1.24 | $31,000.00 |
DisclosureSEC source: 0001599901-25-000168 · wk-form4_1756499311.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person. Read SEC document |
| June 26, 2025 Filed Jun 26, 2025 21:50 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 14,750 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001437749-25-021373 · rdgdoc.xml · derivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Class A Common Stock · 14,750 shares Expires 2035-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 31,540 | $31.06 | $979,563.01 |
DisclosureSEC source: 0001599901-25-000073 · wk-form4_1742596937.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,871 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 62,500 time-based restricted stock units (RSUs) that vested on March 19, 2025. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on September 19, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.06. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:10 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,659 | $28.59 | $161,816.84 |
DisclosureSEC source: 0001599901-25-000035 · wk-form4_1737681000.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,411 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.33. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:10 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 4,738 | $28.59 | $135,474.58 |
DisclosureSEC source: 0001599901-25-000035 · wk-form4_1737681000.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 343,070 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.08. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $31.42 | $0.00 |
DisclosureSEC source: 0001599901-25-000021 · wk-form4_1736385890.xml · derivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 82,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000021 · wk-form4_1736385890.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,808 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 23:15 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 31,855 | $32.66 | $1,040,384.30 |
DisclosureSEC source: 0001599901-24-000205 · wk-form4_1734650152.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,308 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 62,500 time-based restricted stock units (RSUs) that vested on December 17, 2024. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on June 17, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $32.66. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 01:01 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 32,880 | $44.00 | $1,446,723.29 |
DisclosureSEC source: 0001599901-24-000158 · wk-form4_1727139658.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,663 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on September 19, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 19, 2024 Filed Sep 24, 2024 01:01 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000158 · wk-form4_1727139658.xml · nonDerivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 297,163 F4 · shares: As a result of the achievement of the Performance Condition, on September 19, 2024, an additional 25,000 PSUs were earned by the Reporting Person. On such date, such PSUs converted to time-based restricted stock units that will vest in full on March 19, 2025, subject to the Reporting Person's continued employment or service through such date. Read SEC document |
| September 19, 2024 Filed Sep 24, 2024 01:01 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000158 · wk-form4_1727139658.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,543 F1 · shares: Represents performance-based restricted stock units (PSUs). Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on September 11, 2023, and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the second performance objective (the Issuer's completion of a clinical event related to del-brax) (the Performance Condition). Read SEC document |
| August 06, 2024 Filed Aug 7, 2024 21:46 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000127 · wk-form4_1723067208.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,015 Underlying: Common Stock · 28,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 06, 2024 Filed Aug 7, 2024 21:46 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 28,000 | $43.35 | $1,213,822.40 |
DisclosureSEC source: 0001599901-24-000127 · wk-form4_1723067208.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,043 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $44.51. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2024 Filed Aug 7, 2024 21:46 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 28,000 | $1.24 | $34,720.00 |
DisclosureSEC source: 0001599901-24-000127 · wk-form4_1723067208.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000115 · wk-form4_1720728412.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 489,015 Underlying: Common Stock · 28,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 28,000 | $39.93 | $1,118,082.00 |
DisclosureSEC source: 0001599901-24-000115 · wk-form4_1720728412.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,043 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.70 to $40.52. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 28,000 | $1.24 | $34,720.00 |
DisclosureSEC source: 0001599901-24-000115 · wk-form4_1720728412.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 20:25 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001437749-24-021091 · rdgdoc.xml · derivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Class A Common Stock · 29,500 shares Expires 2034-06-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program. One-third of the option shares vest and become exercisable on June 24, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 22:47 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 32,074 | $39.13 | $1,255,039.58 |
DisclosureSEC source: 0001599901-24-000109 · wk-form4_1718923667.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,543 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on June 17, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $39.13. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:01 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001846253-24-000050 · wk-form4_1719003670.xml · derivative · entry 4 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-18 F4 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:01 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-24-000050 · wk-form4_1719003670.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F3 · derivative.expiration_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:01 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-24-000050 · wk-form4_1719003670.xml · derivative · entry 2 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F1 · derivative.expiration_date: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:01 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001846253-24-000050 · wk-form4_1719003670.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 22:47 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000109 · wk-form4_1718923667.xml · nonDerivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,043 F4 · shares: As a result of the achievement of the Performance Condition, on June 17, 2024, an additional 62,500 PSUs were earned by the Reporting Person on such date. On such date, such PSUs converted to time based restricted stock units that will vest on December 17, 2024, subject to the Reporting Person's continued employment or service through such date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 22:47 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000109 · wk-form4_1718923667.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,617 F1 · shares: Represents performance-based restricted stock units (PSUs). Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on September 11, 2023, and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the first performance objective (the Issuer's initiation of the Phase 3 HARBOR trial for del-desiran) (the Performance Condition). Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,767 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · derivative · entry 9 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 517,015 Underlying: Common Stock · 35,767 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F5 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 35,767 | $40.08 | $1,433,484.13 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · nonDerivative · entry 6 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F4 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.22. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 35,767 | $1.24 | $44,351.08 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · nonDerivative · entry 5 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.